Newsroom | 30124 results

VENLO, Niederlande, und GERMANTOWN, Md.--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) hat heute die Verfügbarkeit von zwei maßgeschneiderten digitalen PCR-Assays für Forschungszwecke (Research Use Only, RUO) bekannt gegeben. Diese sollen Forschungs- und Überwachungsmaßnahmen im Zusammenhang mit dem Ausbruch des Bundibugyo-Ebolavirus unterstützen. Die Assays wurden für den Einsatz mit dem digitalen PCR-System QIAcuity entwickelt und sollen qualifizierten Laboren dabei...

VENLO, Netherlands, & GERMANTOWN, Md.--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the availability of two custom-designed research-use-only (RUO) digital PCR assays to support infectious disease research and surveillance efforts related to the Bundibugyo ebolavirus outbreak. The assays are designed for use with the QIAcuity digital PCR system and are intended to help qualified laboratories evaluate emerging pathogen targets in research, wastewater s...

BELLINGHAM, Wash.--(BUSINESS WIRE)--SPIE, the international society of optics and photonics, announced awarding $351,000 in scholarships that will provide support to 85 SPIE Student Members studying optics, photonics, or a related field. The scholarships range from $3,000 to $11,000 and awardees are selected by the SPIE Scholarship Committee from a roster of applicants. “I am deeply passionate about advancing the inclusion of women and other underrepresented groups in the fields of optics and p...

COLUMBUS, Ohio--(BUSINESS WIRE)--Battelle announced The BLOOM Conference, the new name for its internationally recognized Bioremediation Conference, marking the evolution of an event series it has convened for more than three decades. The BLOOM Conference, which stands for Bioremediation, Land Opportunity, Optimization and Minerals, reflects how environmental remediation has expanded beyond cleanup alone to include land reuse, resource recovery and value creation from complex waste streams. Bio...

加州聖卡洛斯--(BUSINESS WIRE)--(美國商業資訊)-- BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235)是一家全球性腫瘤公司，今日公布HERIZON-GEA-01研究資料已刊登於The New England Journal of Medicine，並將於2026年6月1日於芝加哥舉行的美國臨床腫瘤學會(ASCO)年會上，以口頭報告（快速口頭報告：4010）形式發表。HERIZON-GEA-01臨床試驗評估ZIIHERA® (zanidatamab)聯合化療，並比較加入或不加入TEVIMBRA® (tislelizumab)的療效，對照組為trastuzumab聯合化療，用於一線治療晚期或轉移性HER2陽性胃食道腺癌。 韓國首爾延世大學醫學院延世癌症中心腫瘤內科教授，及該NEJM論文資深作者及ASCO摘要第一作者Sun Young Rha博士表示： 「HERIZON-GEA-01研究結果於The New England Journal of Medicine發表，並於ASCO口頭報告中公布，提供了關...

SAN CARLOS, California--(BUSINESS WIRE)--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), empresa global de oncología, anunció hoy que los datos del estudio HERIZON-GEA-01 fueron publicados en The New England Journal of Medicine y se presentarán en una exposición oral (Rapid Oral Abstract: 4010) durante la reunión anual de la American Society of Clinical Oncology (ASCO), que se celebrará el 1 de junio de 2026 en Chicago. El ensayo clínico HERIZON-GEA-01 evaluó ZIIHERA® (zanidatamab...

SAN CARLOS, Califórnia--(BUSINESS WIRE)--A BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), empresa global de oncologia, anunciou hoje que os dados do estudo HERIZON-GEA-01 foram publicados no The New England Journal of Medicine e serão apresentados em uma sessão oral (Resumo Oral Rápido: 4010) na Reunião Anual da Sociedade Americana de Oncologia Clínica (ASCO), que ocorrerá em 1º de junho de 2026, em Chicago. O ensaio clínico HERIZON-GEA-01 avaliou a associação de ZIIHERA® (zanida...

カリフォルニア州サンカルロス--(BUSINESS WIRE)--（ビジネスワイヤ） -- BeOne Medicines Ltd.（Nasdaq：ONC、HKEX：06160、SSE：688235）は、がん領域のグローバル企業であり、HERIZON-GEA-01のデータがThe New England Journal of Medicineに掲載され、口頭発表（Rapid Oral Abstract：4010）として、シカゴで開催される米国臨床腫瘍学会（ASCO）年次総会において、2026年6月1日に発表されることを明らかにしました。HERIZON-GEA-01臨床試験では、進行／転移性HER2陽性胃食道腺がん（GEA）に対する一次治療として、ZIIHERA®（ザニダタマブ）と化学療法の併用（TEVIMBRA®（チスレリズマブ）併用および非併用）を、トラスツズマブと化学療法の併用からなる対照群と比較評価しました。 韓国・ソウルの延世大学校医科大学延世がんセンターの腫瘍内科学教授であり、NEJM論文の上席著者およびASCO抄録の筆頭著者であるSun Young Rha氏は、次のように...

SAN CARLOS, Calif.--(BUSINESS WIRE)--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), azienda oncologica globale, oggi ha reso noto che i dati dallo studio HERIZON-GEA-01 sono stati pubblicati in The New England Journal of Medicine e verranno illustrati in una presentazione orale (Rapid Oral Abstract: 4010) nell'ambito del Meeting annuale dell'American Society of Clinical Oncology (ASCO) che si terrà a Chicago il 1° giugno 2026. Il testo originale del presente annuncio, redatto nel...

SAN CARLOS, Calif.--(BUSINESS WIRE)--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), een wereldwijd oncologiebedrijf, heeft vandaag aangekondigd dat gegevens van HERIZON-GEA-01 zijn gepubliceerd in The New England Journal of Medicine en zullen worden gepresenteerd in een mondelinge presentatie (Rapid Oral Abstract: 4010) op de jaarlijkse bijeenkomst van de American Society of Clinical Oncology (ASCO) op 1 juni 2026 in Chicago. Deze bekendmaking is officieel geldend in de originele...